Treatment should be continued by women who are found to be pregnant after the first trimester. If pregnancy is recognised during the first trimester, the risks and benefits of antiretroviral therapy should be discussed. The woman may choose to temporarily discontinue treatment until after the first trimester, in which case all agents should be stopped and restarted simultaneously .

A history of AZT treatment prior to pregnancy should not alter recommendations for AZT use during pregnancy, during labor and by the new-born child to reduce perinatal transmission.

Women who are not currently using AZT should be advised to add or substitute it for another nucleoside analogue after 14 weeks gestation.